Goldman Sachs raises target for Roche Holding stock to CHF 391.00

Published on 10/26/2026 at 10:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roche posted CHF 46.5 billion in nine-month sales on October 22, 2026. Roche Holding stock costs EUR 429.48, 0.17 percent below Xetra.

Growth and pipeline dates

Goldman Sachs lifted its Roche target from CHF 376.00 to CHF 391.00 on October 23, 2026.
Roche reported CHF 46.5 billion in nine-month sales for 2026, up 6 percent at constant exchange rates.
Roche Holding stock trades at EUR 429.48 at 10:30 a.m. CEST at Lang & Schwarz on October 26, 2026, 0.17 percent below the Xetra close of October 23, 2026.
Roche has an investor conference on November 2, 2026, and a giredestrant FDA decision date on November 30, 2026.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Roche Holding (ISIN CH1499059983) was trading at EUR 429.48 at Lang & Schwarz on October 26, 2026 at 10:30 a.m. CEST, 0.17 percent below the Xetra close of October 23, 2026. Goldman Sachs raised its Roche target from CHF 376.00 to CHF 391.00 while maintaining a Neutral rating on October 23, 2026, according to MarketScreener.

Sales growth meets firm guidance

Roche's latest operating update points to a stronger reported quarter, but the currency effect remains important. In the first nine months of 2026, group sales reached CHF 46.5 billion, up 6 percent at constant exchange rates and 1 percent in Swiss francs from CHF 45.9 billion in the prior-year period, according to the Roche release dated October 22, 2026.

The Pharmaceuticals division generated CHF 36.2 billion in sales, up 7 percent at constant exchange rates, while Diagnostics contributed CHF 10.3 billion, up 4 percent on the same basis. Roche confirmed mid-single-digit group sales growth and high-single-digit core earnings per share growth for 2026.

What do the next dates mean?

The chronology shows three important steps. On September 23, 2026, Roche reported interim sefaxersen data showing a 43.1 percent reduction in proteinuria. On October 22, 2026, the company reported CHF 46.5 billion in nine-month sales and reaffirmed its outlook. On October 23, 2026, Goldman Sachs increased its target to CHF 391.00 from CHF 376.00. The sequence puts pipeline execution alongside the current sales base.

The next dated items are an investor conference on November 2, 2026, listed on Roche's investor calendar, and the FDA's November 30, 2026, goal date for giredestrant in early-stage breast cancer, stated in the company's sales update. The latter date gives the pipeline a clear regulatory checkpoint.

Stock stays close to the Xetra close

For investors, the key contrast is between operational growth and a modest euro quotation move. Roche's reported sales growth supports the latest guidance, while the Lang & Schwarz price remains EUR 0.72 below the Xetra close used for the daily comparison.

The further course of trading is shown by the continuously updated real-time quote of Roche Holding stock.